Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Idiopathic thrombocytopenic purpura Stories

2009-11-30 07:51:00

THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition...

2009-11-23 14:05:00

THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London. The Best Overall Pipeline award was presented to Amgen by Scrip in recognition of the size, quality, novelty and market potential of the company's pipeline, as well as its mix of candidates across development stages. According to the...

2009-10-01 04:00:00

NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition. Novartis Oncology, Amgen, GlaxoSmithKline and Veridex were honored with the 2009 Prix Galien USA, considered the industry's highest accolade for pharmaceutical research and development, for treatments that could change the course of health care...

2009-09-23 08:49:00

LACHEN, SWITZERLAND and HOBOKEN, N.J., Sept. 23 /PRNewswire/ -- Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can...

2009-06-07 02:43:00

BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences...

2009-04-22 13:15:00

18 patient advocacy and health care professional groups join with Congressional sponsors Reps. Israel, Brady and Schwartz to announce new legislation; call for patient access to IVIG WASHINGTON, April 22 /PRNewswire-USNewswire/ -- Members of Congress and patient advocacy groups announced today the introduction of new legislation - H.R. 2002, Medicare Patient IVIG Access Act of 2009 - meant to remedy inadequate Medicare reimbursements that currently restrict patient access to Intravenous...

2009-02-06 16:45:00

First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder ZUG, Switzerland, Feb. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids,...

2009-01-20 07:30:00

SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chinese State Food and Drug Administration (SFDA) for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) in China. If the extension is approved, 3SBio expects...

2008-12-08 13:00:00

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a chronic and serious autoimmune disorder characterized by lower than expected platelet counts in the blood, sometimes leading to serious bleeding events. The results were presented today as an...

2008-12-06 11:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, will be presented in a press conference on Saturday, December 6, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. The studies featured in the press conference will...